Intelligent Bio Solutions (INBS)
Market Price (8/13/2026): $2.55 | Market Cap: $4.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Intelligent Bio Solutions (INBS)
Market Price (8/13/2026): $2.55Market Cap: $4.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -124% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 33% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Non-Invasive Drug Screening. | Weak multi-year price returns2Y Excs Rtn is -127%, 3Y Excs Rtn is -170% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -285% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -280%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -289% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -291% High stock price volatilityVol 12M is 177% Key risksINBS key risks include [1] severe financial distress and operational inefficiencies, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -124% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 33% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Non-Invasive Drug Screening. |
| Weak multi-year price returns2Y Excs Rtn is -127%, 3Y Excs Rtn is -170% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -285% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -280%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -289% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -291% |
| High stock price volatilityVol 12M is 177% |
| Key risksINBS key risks include [1] severe financial distress and operational inefficiencies, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Intelligent Bio Solutions (INBS) stock has gained about 5% since 4/30/2026 because of the following key factors:
1. Consistent advancement towards U.S. market entry through FDA 510(k) submission milestones.
Intelligent Bio Solutions has made significant progress in its regulatory pathway for the Intelligent Fingerprinting Drug Screening System, including the completion of crucial studies supporting its FDA 510(k) application. Key announcements within this period include the initiation of a clinical study in June 2026, followed by the completion of precision testing in fiscal Q1 2027 (July 2026), an interference study in fiscal Q1 2027 (August 2026), a usability study in fiscal Q1 2027 (August 2026), and a method comparison study in fiscal Q1 2027 (August 2026).
2. Validation of the Intelligent Fingerprinting Drug Screening System through successful study completions.
The company announced the successful completion of several critical studies, such as the Usability Study, Interference Study, and Method Comparison Study, all designed to support the FDA 510(k) submission for U.S. market clearance, specifically for codeine detection. These studies reinforce the system's effectiveness and operability, demonstrating that it can be accurately used by non-specialist operators and performs well against everyday substances.
Show more
Intelligent Bio Solutions (INBS) stock has gained about 5% since 4/30/2026 because of the following key factors:
1. Consistent advancement towards U.S. market entry through FDA 510(k) submission milestones.
Intelligent Bio Solutions has made significant progress in its regulatory pathway for the Intelligent Fingerprinting Drug Screening System, including the completion of crucial studies supporting its FDA 510(k) application. Key announcements within this period include the initiation of a clinical study in June 2026, followed by the completion of precision testing in fiscal Q1 2027 (July 2026), an interference study in fiscal Q1 2027 (August 2026), a usability study in fiscal Q1 2027 (August 2026), and a method comparison study in fiscal Q1 2027 (August 2026).
2. Validation of the Intelligent Fingerprinting Drug Screening System through successful study completions.
The company announced the successful completion of several critical studies, such as the Usability Study, Interference Study, and Method Comparison Study, all designed to support the FDA 510(k) submission for U.S. market clearance, specifically for codeine detection. These studies reinforce the system's effectiveness and operability, demonstrating that it can be accurately used by non-specialist operators and performs well against everyday substances.
3. Anticipation of entering the multi-billion-dollar U.S. drug screening market in calendar H2 2026.
The continuous positive updates regarding the FDA 510(k) submission process have kept Intelligent Bio Solutions on track for its planned entry into the U.S. drug screening market in the second half of calendar year 2026. This potential market entry represents a substantial growth opportunity and a significant expansion beyond its current international operations.
Show less
Stock Movement Drivers
Fundamental Drivers
The 3.7% change in INBS stock from 4/30/2026 to 8/12/2026 was primarily driven by a 59.1% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.45 | 2.54 | 3.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 4 | 9.3% |
| P/S Multiple | 0.7 | 1.0 | 59.1% |
| Shares Outstanding (Mil) | 1 | 2 | -40.4% |
| Cumulative Contribution | 3.7% |
Market Drivers
4/30/2026 to 8/12/2026| Return | Correlation | |
|---|---|---|
| INBS | 3.7% | |
| Market (SPY) | 7.5% | 10.7% |
| Sector (XLV) | 15.4% | -6.3% |
Fundamental Drivers
The -70.8% change in INBS stock from 1/31/2026 to 8/12/2026 was primarily driven by a -54.1% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.69 | 2.54 | -70.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 4 | 18.9% |
| P/S Multiple | 2.3 | 1.0 | -54.1% |
| Shares Outstanding (Mil) | 1 | 2 | -46.4% |
| Cumulative Contribution | -70.8% |
Market Drivers
1/31/2026 to 8/12/2026| Return | Correlation | |
|---|---|---|
| INBS | -70.8% | |
| Market (SPY) | 11.9% | 19.8% |
| Sector (XLV) | 9.3% | 11.2% |
Fundamental Drivers
The -83.9% change in INBS stock from 7/31/2025 to 8/12/2026 was primarily driven by a -66.7% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.80 | 2.54 | -83.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 4 | 33.3% |
| P/S Multiple | 3.1 | 1.0 | -66.7% |
| Shares Outstanding (Mil) | 1 | 2 | -63.8% |
| Cumulative Contribution | -83.9% |
Market Drivers
7/31/2025 to 8/12/2026| Return | Correlation | |
|---|---|---|
| INBS | -83.9% | |
| Market (SPY) | 23.3% | 6.9% |
| Sector (XLV) | 30.8% | -3.5% |
Fundamental Drivers
The -98.8% change in INBS stock from 7/31/2023 to 8/12/2026 was primarily driven by a -99.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8122026 | Change |
|---|---|---|---|
| Stock Price ($) | 216.00 | 2.54 | -98.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 4 | 380.9% |
| P/S Multiple | 2.5 | 1.0 | -57.8% |
| Shares Outstanding (Mil) | 0 | 2 | -99.4% |
| Cumulative Contribution | -98.8% |
Market Drivers
7/31/2023 to 8/12/2026| Return | Correlation | |
|---|---|---|
| INBS | -98.8% | |
| Market (SPY) | 74.7% | 11.1% |
| Sector (XLV) | 31.5% | 0.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| INBS Return | -81% | -86% | -92% | -65% | -32% | -78% | -100% |
| Peers Return | 29% | -25% | 15% | -9% | 2% | 29% | 33% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| INBS Win Rate | 17% | 33% | 33% | 33% | 50% | 25% | |
| Peers Win Rate | 67% | 42% | 44% | 44% | 56% | 66% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| INBS Max Drawdown | -85% | -89% | -99% | -84% | -84% | -91% | |
| Peers Max Drawdown | -22% | -41% | -27% | -26% | -22% | -19% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABT, OSUR, DGX, LH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/12/2026 (YTD)
How Low Can It Go
| Event | INBS | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -40.9% | -7.8% |
| % Gain to Breakeven | 69.2% | 8.5% |
| Time to Breakeven | 25 days | 18 days |
In The Past
Intelligent Bio Solutions's stock fell -40.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 69.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | INBS | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -40.9% | -7.8% |
| % Gain to Breakeven | 69.2% | 8.5% |
| Time to Breakeven | 25 days | 18 days |
In The Past
Intelligent Bio Solutions's stock fell -40.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 69.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Intelligent Bio Solutions (INBS)
Intelligent Bio Solutions (INBS) is a biosensor diagnostic technology company focused on developing non-invasive solutions for health monitoring and disease detection. Its flagship product is the Saliva Glucose Biosensor, a novel device designed to measure glucose levels using saliva, thereby offering a non-invasive alternative to traditional blood-based glucose monitoring for individuals managing diabetes.
Beyond its primary glucose biosensor, Intelligent Bio Solutions is actively developing a biosensor test for COV2, intended to complement existing RNA virus detection methods. The company's long-term strategy involves building a comprehensive biosensor platform with broader diagnostic capabilities, including applications in biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostics. This platform development is supported by a research agreement with Johns Hopkins Bloomberg School of Public Health.
Intelligent Bio Solutions primarily serves the medical diagnostics market. Its current and pipeline products are designed for applications ranging from personal health management (e.g., non-invasive glucose monitoring) to clinical diagnostics and public health initiatives (e.g., COV2 testing). The company aims to provide less invasive, more convenient, and potentially more accessible diagnostic tools for patients, healthcare professionals, and laboratories globally.
```AI Analysis | Feedback
Here are 1-2 brief analogies for Intelligent Bio Solutions (INBS):
It's like a Clearblue (pregnancy test) for rapid drug screening, but using a fingerprint sweat sample.
Imagine 23andMe, but instead of genetics from saliva, it's detecting drugs from a fingerprint sweat sample.
AI Analysis | Feedback
- Saliva Glucose Biosensor: A non-invasive diagnostic device that uses saliva to measure glucose levels.
- COV2 Test: A biosensor test designed to complement RNA virus detection for COVID-19 diagnosis.
- Biosensor Platform: A diagnostic platform encompassing biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic capabilities.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Harry Simeonidis
President and Chief Executive Officer
Harry Simeonidis was appointed Chief Executive Officer of Intelligent Bio Solutions in October 2022. He brings over 25 years of experience in healthcare, pharmaceutical, and life sciences, holding various senior management positions across Asia Pacific. Before joining Intelligent Bio Solutions, Mr. Simeonidis served as the General Manager, Surgery, Asia Pacific, at GE Healthcare, where he oversaw significant market expansion. Prior to this, he was the President and CEO of GE Healthcare ANZ for nine years. He also served as a non-executive Director of Farmaforce Limited.
Spiro Sakiris
Chief Financial Officer
Spiro Sakiris is a seasoned finance professional with over 34 to 35 years of expertise in accounting, taxation, Initial Public Offerings (IPOs), capital raising, and business system designs. His experience includes applying International Financial Reporting Standards (IFRS) and US Generally Accepted Accounting Principles (GAAP) within the life science sector. Mr. Sakiris is a member of the Institute of Chartered Accountants of Australia & New Zealand.
Callistus Sequeira
Vice President of Global Quality and Operations
Callistus Sequeira serves as the Vice President of Global Quality and Operations for Intelligent Bio Solutions.
Doug Heath
Vice President of Global Sales
Doug Heath is a senior sales professional with over a decade of experience leading commercial strategies across global markets. Earlier in his career, Mr. Heath contributed to several large-scale infrastructure projects in the Middle East. As Vice President of Global Sales, he has been instrumental in driving sales and expanding Intelligent Bio Solutions' market presence.
Anna Turkington
Vice President of Marketing
Anna Turkington is a senior marketing and communications specialist with over ten years of experience in corporate and non-profit sectors.
AI Analysis | Feedback
Here are the key risks to Intelligent Bio Solutions (INBS) in order from most significant to less significant:
- Financial Health and Going Concern: Intelligent Bio Solutions faces substantial financial challenges, characterized by a negative Altman Z-Score of -11.74, which indicates significant financial distress and a high risk of bankruptcy within two years. The company also exhibits poor business operations, reflected in a Piotroski F-Score of 2, and reports significant operational inefficiencies with negative operating and net margins. Furthermore, a current ratio of 0.89 suggests potential liquidity issues. These factors collectively highlight a dominant risk to the company's ability to continue as a going concern.
- Regulatory Approval for U.S. Market Entry: A critical component of Intelligent Bio Solutions' growth strategy is the planned entry into the substantial U.S. drug screening market with its Intelligent Fingerprinting Drug Testing Solution. The company submitted its FDA 510(k) pre-market application in December 2024, with a U.S. market launch anticipated for 2025. The successful attainment of FDA clearance is crucial to unlock this market opportunity. Any delays in securing regulatory approvals or a failure to obtain them would severely impede the company's commercialization plans and revenue growth.
- Market Adoption of New Technology and Competition: Intelligent Bio Solutions' fingerprint sweat analysis technology offers a novel, non-invasive, hygienic, and rapid alternative to traditional drug testing methods such as urine and saliva tests. While the technology presents several advantages, there is an inherent risk concerning the rate and extent of its adoption in a competitive market with established testing protocols and existing players. Successfully disrupting the traditional testing landscape and gaining significant market share remains a continuous challenge for the company.
AI Analysis | Feedback
The continued advancement and market dominance of continuous glucose monitoring (CGM) systems. While minimally invasive, these established technologies provide continuous glucose data, which offers significant advantages for diabetes management over a discrete, non-continuous saliva-based measurement. As CGMs become smaller, more accurate, and widely adopted, they could significantly reduce the market appeal and demand for INBS’s saliva glucose biosensor.
AI Analysis | Feedback
Intelligent Bio Solutions (INBS) operates in two primary markets: fingerprint-based drug screening and glucose biosensors for diabetes management.
Fingerprint Drug Screening System
The company's Intelligent Fingerprinting Drug Screening System targets the global drug screening market, particularly the workplace drug testing segment.
- The global drug screening market was valued at approximately USD 13.8 billion in 2024 and is projected to reach USD 52.2 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 14.5% from 2025 to 2034. Another estimate places the global market at USD 8.49 billion in 2025, with a projected growth to USD 20.86 billion by 2031 at a CAGR of 16.16%.
- In the United States, the drug screening market was valued at USD 5.9 billion in 2024 and is projected to grow to USD 21.2 billion by 2034, with a CAGR of 14%. Another report states the U.S. market size was USD 5.801.7 million (USD 5.8017 billion) in 2025, with an estimated increase to USD 11.216.8 million (USD 11.2168 billion) by 2034 at a CAGR of 7.37%.
- The workplace programs segment represented 34.58% of global drug screening revenue in 2025. In the U.S., workplaces accounted for 33.6% of the drug screening market share. The global employer and workplace drug testing market was estimated at USD 6.33 billion in 2025 and is projected to reach USD 9.09 billion by 2033, growing at a CAGR of 4.7% from 2026 to 2033. The U.S. employer and workplace drug testing market was estimated at USD 2.57 billion in 2024 and is projected to reach USD 4.01 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033.
Saliva Glucose Biosensor
Intelligent Bio Solutions is also developing a saliva glucose biosensor as part of its Biosensor Platform for chronic disease management.
- The global saliva glucose biosensor market was valued at USD 14.78 billion in 2024 and is anticipated to reach USD 30.55 billion by 2032, expanding at a CAGR of 9.5%.
- More broadly, the global glucose biosensors market size was estimated at USD 9.68 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. Another projection indicates the global glucose biosensors market will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91%.
- North America dominates the global glucose biosensors market, holding 32.62% of the revenue share in 2024, and 34% of the market in 2024. The U.S. glucose biosensors market size is projected to exceed USD 23.08 billion by 2034, increasing from USD 10.71 billion in 2025.
AI Analysis | Feedback
- Entry into the U.S. Drug Screening Market: The company is actively pursuing FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System to enter the multi-billion dollar U.S. drug screening market. Clinical studies are underway to support this submission, with full data analysis anticipated by the end of March 2026 and planned commercial launch into this significant market.
- Expansion of the Installed Base of Readers and Recurring Cartridge Sales: Intelligent Bio Solutions operates on a "razor-razorblade" business model, where the sale of its drug screening readers drives recurring revenue from consumable cartridges. The company has demonstrated strong growth in reader sales, which more than doubled year-over-year in fiscal Q2 2026, leading to a significant expansion of its installed base and consequently boosting cartridge sales.
- Growth in International Customer Base and Market Penetration: The company has an established and diverse customer base across 24 countries in industries such as construction, manufacturing, transport, logistics, drug treatment, and law enforcement. Intelligent Bio Solutions has reported substantial year-over-year revenue growth due to strong adoption of its technology and an expanding global sales and distribution network.
- New Manufacturing Partnership for Scalability and Improved Margins: A strategic manufacturing partnership with Syrma Johari MedTech Ltd. is expected to enhance global production capabilities, increase gross margins, and support the company's planned entry into the U.S. market. This collaboration is projected to yield over 40% in annual production cost savings and approximately 20 percentage points in gross margin improvement annually.
- Introduction of New Products and Broader Applications: While focusing on its fingerprinting system, Intelligent Bio Solutions is also developing complementary products such as the SmarTest® Sweat Drug Testing Patch. This wearable device offers longer-term drug monitoring, expanding the company's testing solutions and potential revenue streams in settings like justice and rehabilitation.
AI Analysis | Feedback
Share Issuance
- Intelligent Bio Solutions completed a private placement expected to close around January 2, 2026, raising approximately $10.0 million in gross proceeds. This involved selling 2,298,850 common shares (or pre-funded warrants) and issuing Series K-1 and K-2 warrants to purchase an additional 2,298,850 shares each at an exercise price of $4.10. The combined purchase price for these securities was $4.35 per share (or pre-funded warrant) plus associated warrants.
- The number of shares outstanding for Intelligent Bio Solutions increased by 126.93% in one year, leading to substantial shareholder dilution in the past year.
- The proceeds from the $10 million private placement are intended for working capital and general corporate purposes.
Inbound Investments
- Intelligent Bio Solutions raised approximately $10.0 million through a private placement of common shares (or pre-funded warrants) and associated warrants, with the closing anticipated around January 2, 2026.
- The company successfully closed a $10 million private placement.
Capital Expenditures
- In the last 12 months (prior to March 16, 2026), Intelligent Bio Solutions reported capital expenditures of -$361,535.
Peer Outperformance in Life Sciences Tools & Services
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.5% | 71.6% | 176.5% | CAH 405% · MCK 354% · SNYR 198% |
| Health Care Services | 20 | 24.8% | 33.4% | 10.1% | HIMS 258% · RDNT 152% · DGX 77% |
| Managed Health Care | 8 | 51.3% | -4.8% | 7.2% | OSCR 101% · HQY 54% · ELV 17% |
| Health Care Equipment | 51 | -2.7% | -10.6% | -17.3% | POCI 10275% · UFPT 417% · GKOS 281% |
| Health Care Facilities | 24 | 12.4% | -11.0% | -18.8% | THC 281% · NHC 239% · ENSG 120% |
| Health Care Supplies | 12 | 41.4% | -12.0% | -25.5% | LNTH 295% · HAE 49% · MMSI 38% |
| Pharmaceuticals | 64 | 4.2% | -3.0% | -40.0% | LQDA 2862% · INDV 1521% · ETON 841% |
| Health Care Technology | 21 | -15.2% | -55.4% | -72.3% | SPOK 135% · TALK 0% · HSTM -6% |
| Life Sciences Tools & Services ← | 111 | -4.3% | -34.4% | -72.6% | SNWV 2092% · ELMD 263% · MEDP 236% |
| Biotechnology | 372 | 12.1% | -29.2% | -77.3% | BRTX 106050% · DNTH 1643% · CELZ 1614% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Intelligent Bio Solutions Earnings Notes | 12/16/2025 | |
| Can Intelligent Bio Solutions Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 110.91 |
| Mkt Cap | 26.4 |
| Rev LTM | 11,560 |
| Op Inc LTM | 1,629 |
| FCF LTM | 1,155 |
| FCF 3Y Avg | 1,090 |
| CFO LTM | 1,638 |
| CFO 3Y Avg | 1,573 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.1% |
| Rev Chg 3Y Avg | 6.5% |
| Rev Chg Q | 10.2% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | -2.2% |
| Op Inc Chg 3Y Avg | 6.5% |
| Op Mgn LTM | 11.4% |
| Op Mgn 3Y Avg | 9.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 11.4% |
| CFO/Rev 3Y Avg | 11.7% |
| FCF/Rev LTM | 8.1% |
| FCF/Rev 3Y Avg | 8.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales of goods - cartridges | 2 | |||
| Sales of goods - readers | 1 | |||
| Other sales - accessories | 1 | |||
| Commercially available Intelligent Fingerprinting Products (IFPG) | 3 | 1 | ||
| Development Stage Biosensor Platform Technology (BPT) | 0 | 0 | ||
| Government support income | 0 | |||
| Total | 3 | 3 | 1 | 0 |
| $ Mil | 2024 | 2023 | 2021 | 2020 |
|---|---|---|---|---|
| Commercially available Intelligent Fingerprinting Products (IFPG) | 5 | 7 | ||
| Development Stage Biosensor Platform Technology (BPT) | 1 | 1 | ||
| Single segment | 22 | 2 | ||
| Total | 6 | 7 | 22 | 2 |
Price Behavior
| Market Price | $2.54 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/23/2020 | |
| Distance from 52W High | -86.5% | |
| 50 Days | 200 Days | |
| DMA Price | $2.14 | $4.91 |
| DMA Trend | down | down |
| Distance from DMA | 18.9% | -48.3% |
| 3M | 1YR | |
| Volatility | 88.0% | 177.3% |
| Downside Capture | 233.87 | 184.37 |
| Upside Capture | -5.31 | -59.13 |
| Correlation (SPY) | 12.3% | 5.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.21 | 0.68 | 1.04 | 1.46 | 0.96 | 1.41 |
| Up Beta | 3.80 | 1.32 | -1.16 | 1.91 | 1.65 | 1.27 |
| Down Beta | -1.04 | -0.02 | -0.57 | 0.32 | 1.70 | 0.76 |
| Up Capture | -70% | -40% | 121% | -25% | -35% | 32% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 17 | 26 | 40 | 89 | 300 |
| Down Capture | 277% | 167% | 253% | 231% | 155% | 112% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 14 | 26 | 37 | 85 | 159 | 436 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INBS | |
|---|---|---|---|---|
| INBS | -82.5% | 176.9% | -0.36 | - |
| Sector ETF (XLV) | 31.1% | 15.5% | 1.54 | -3.3% |
| Equity (SPY) | 22.6% | 12.8% | 1.32 | 6.1% |
| Gold (GLD) | 31.4% | 28.4% | 0.95 | 5.2% |
| Commodities (DBC) | 37.9% | 20.1% | 1.48 | 1.5% |
| Real Estate (VNQ) | 14.3% | 13.8% | 0.73 | -2.4% |
| Bitcoin (BTCUSD) | -46.5% | 42.9% | -1.33 | 8.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INBS | |
|---|---|---|---|---|
| INBS | -79.5% | 214.9% | -0.07 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.24 | 1.9% |
| Equity (SPY) | 13.4% | 17.2% | 0.60 | 9.6% |
| Gold (GLD) | 19.0% | 18.6% | 0.83 | 2.7% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | 2.8% |
| Real Estate (VNQ) | 2.2% | 18.9% | 0.01 | 4.0% |
| Bitcoin (BTCUSD) | 9.9% | 52.8% | 0.37 | 8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INBS | |
|---|---|---|---|---|
| INBS | -60.3% | 206.6% | -0.15 | - |
| Sector ETF (XLV) | 10.2% | 16.6% | 0.50 | 1.9% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 9.6% |
| Gold (GLD) | 12.0% | 16.2% | 0.61 | 2.9% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 2.8% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 3.7% |
| Bitcoin (BTCUSD) | 60.9% | 66.1% | 1.01 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | 3.0% | -29.1% | -39.8% |
| 2/12/2026 | -6.7% | -9.3% | -23.8% |
| 11/12/2025 | -9.6% | -13.6% | -30.6% |
| 8/15/2025 | 2.0% | 0.7% | 27.9% |
| 5/13/2025 | -5.5% | -5.9% | 39.7% |
| 2/13/2025 | 7.6% | -6.8% | -11.4% |
| 11/7/2024 | -5.2% | -11.6% | -2.9% |
| 9/19/2024 | 4.7% | 3.1% | -12.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 5 | 5 |
| # Negative | 11 | 14 | 14 |
| Median Positive | 5.3% | 7.2% | 27.9% |
| Median Negative | -6.7% | -10.5% | -28.4% |
| Max Positive | 92.5% | 150.7% | 39.7% |
| Max Negative | -17.5% | -38.7% | -63.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | 3.0% | -29.1% | -39.8% |
| 2/12/2026 | -6.7% | -9.3% | -23.8% |
| 11/12/2025 | -9.6% | -13.6% | -30.6% |
| 8/15/2025 | 2.0% | 0.7% | 27.9% |
| 5/13/2025 | -5.5% | -5.9% | 39.7% |
| 2/13/2025 | 7.6% | -6.8% | -11.4% |
| 11/7/2024 | -5.2% | -11.6% | -2.9% |
| 9/19/2024 | 4.7% | 3.1% | -12.5% |
| 5/8/2024 | -1.2% | -6.4% | -22.0% |
| 2/9/2024 | -11.3% | -34.7% | -31.3% |
| 11/8/2023 | 92.5% | 150.7% | 32.2% |
| 8/25/2023 | -0.5% | -3.8% | -38.3% |
| 5/12/2023 | 6.5% | 7.2% | 27.2% |
| 2/15/2023 | 5.3% | -23.0% | -63.6% |
| 11/9/2022 | -3.5% | -5.0% | -26.4% |
| 8/31/2022 | -8.6% | -18.9% | -33.9% |
| 5/11/2022 | 5.4% | 18.6% | 10.5% |
| 2/10/2022 | -17.5% | -38.7% | -22.5% |
| 11/17/2021 | -7.2% | -8.3% | -30.4% |
| SUMMARY STATS | |||
| # Positive | 8 | 5 | 5 |
| # Negative | 11 | 14 | 14 |
| Median Positive | 5.3% | 7.2% | 27.9% |
| Median Negative | -6.7% | -10.5% | -28.4% |
| Max Positive | 92.5% | 150.7% | 39.7% |
| Max Negative | -17.5% | -38.7% | -63.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/12/2026 | 10-Q |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/15/2025 | 10-K |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 09/18/2024 | 10-K |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-Q |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/23/2023 | 10-K |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/22/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/12/2026 | 10-Q |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/15/2025 | 10-K |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 09/18/2024 | 10-K |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-Q |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/23/2023 | 10-K |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/22/2022 | 10-K |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 02/11/2022 | 10-Q |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 09/16/2021 | 10-K |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 02/12/2021 | 10-Q |
| 09/30/2020 | 12/26/2020 | 424B4 |
| 03/31/2020 | 08/06/2020 | S-1/A |
| 09/30/2019 | 11/29/2019 | S-1/A |
| 06/30/2019 | 08/21/2019 | S-1/A |
| 03/31/2019 | 07/05/2019 | S-1 |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.